Nutra Pharma Corp. (NPHC)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Mar 3, 2026
Nutra Pharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 0.39 | 0.59 | 0.44 | 0.1 | 0.05 | Upgrade
|
| Revenue Growth (YoY) | -34.08% | 35.73% | 348.43% | 88.33% | -50.29% | Upgrade
|
| Cost of Revenue | 0.14 | 0.2 | 0.19 | 0.09 | 0.04 | Upgrade
|
| Gross Profit | 0.25 | 0.4 | 0.25 | 0.01 | 0.01 | Upgrade
|
| Selling, General & Admin | 1.13 | 1.18 | 2.08 | 1.93 | 1.1 | Upgrade
|
| Operating Expenses | 1.13 | 1.28 | 2.16 | 2 | 0.94 | Upgrade
|
| Operating Income | -0.88 | -0.89 | -1.91 | -1.99 | -0.92 | Upgrade
|
| Interest Expense | -0.32 | -0.4 | -0.79 | -0.5 | -0.34 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.12 | -0.11 | 11.03 | -10.13 | -1.1 | Upgrade
|
| EBT Excluding Unusual Items | -1.32 | -1.4 | 8.33 | -12.61 | -2.36 | Upgrade
|
| Other Unusual Items | 0.03 | 0.01 | -0.15 | -0.49 | 1.59 | Upgrade
|
| Pretax Income | -1.29 | -1.39 | 8.18 | -13.1 | -0.77 | Upgrade
|
| Net Income | -1.29 | -1.39 | 8.18 | -13.1 | -0.77 | Upgrade
|
| Net Income to Common | -1.29 | -1.39 | 8.18 | -13.1 | -0.77 | Upgrade
|
| Shares Outstanding (Basic) | 7,674 | 7,608 | 7,503 | 7,233 | 6,607 | Upgrade
|
| Shares Outstanding (Diluted) | 7,674 | 7,608 | 19,097 | 7,233 | 6,607 | Upgrade
|
| Shares Change (YoY) | 0.87% | -60.16% | 164.03% | 9.46% | 40.28% | Upgrade
|
| EPS (Basic) | -0.00 | -0.00 | 0.00 | -0.00 | -0.00 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.00 | 0.00 | -0.00 | -0.00 | Upgrade
|
| Free Cash Flow | -0.42 | -0.55 | -0.82 | -1.78 | -0.88 | Upgrade
|
| Gross Margin | 63.07% | 66.64% | 56.82% | 8.66% | 28.74% | Upgrade
|
| Operating Margin | -224.00% | -149.10% | -435.21% | -2034.53% | -1782.27% | Upgrade
|
| Profit Margin | -327.85% | -234.22% | 1865.70% | -13399.01% | -1482.14% | Upgrade
|
| Free Cash Flow Margin | -108.11% | -92.46% | -187.19% | -1824.84% | -1703.36% | Upgrade
|
| EBITDA | -0.87 | -0.87 | -1.88 | -1.98 | -0.92 | Upgrade
|
| EBITDA Margin | -222.10% | -146.05% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.01 | 0.02 | 0.02 | 0.01 | 0 | Upgrade
|
| EBIT | -0.88 | -0.89 | -1.91 | -1.99 | -0.92 | Upgrade
|
| EBIT Margin | -224.00% | -149.10% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.